title: Oral administration of paramylon, a beta-1,3-D-glucan isolated from Euglena gracilis Z inhibits development of atopic dermatitis-like skin lesions in NC/Nga mice.
abstract: Paramylon is a beta-1,3-D-glucan isolated from Euglena gracilis Z. This study was designed to evaluate the suppressive effects of the oral administration of paramylon on the development of atopic dermatitis (AD)-like skin lesions induced by repeated application of 2,4,6-trinitrochlorobenzene (TNCB) in sensitized NC/Nga mice. The effects of paramylon were assessed by measuring macroscopical and histopathological findings of skin, ear swelling, serum levels of total IgE, interleukin-4 (IL-4) and interferon-gamma (IFN-gamma) and IL-18 and IL-12 contents in the skin lesions. Oral administration of paramylon inhibited the development of AD-like skin lesions as exemplified by a significant decrease in dermatitis scores for the back, ear swelling and hypertrophy of the skin, infiltration of inflammatory cells in the skin, and serum IgE levels. Oral administration of paramylon reduced serum levels of both IL-4 and IFN-gamma and IL-18 and IL-12 contents in the skin lesions. Oral administration of paramylon did not cause weight loss, as was observed with prednisolone. These results suggest that paramylon inhibits the development of AD-like skin lesions in NC/Nga mice by suppressing both the T-helper (Th) 1 and Th 2 cell responses. Our results indicate that paramylon treatment could provide an effective alternative therapy for the management of AD.
authors.affiliation: Course of Veterinary Laboratory Medicine, School of Veterinary Medicine, Faculty of Agriculture, Tottori University, Japan. sugiyama@muses.tottori-u.ac.jp
authors.forename: Akihiko
authors.initials: A
authors.lastname: Sugiyama
authors.forename: Sayaka
authors.initials: S
authors.lastname: Hata
authors.forename: Kengo
authors.initials: K
authors.lastname: Suzuki
authors.forename: Eriko
authors.initials: E
authors.lastname: Yoshida
authors.forename: Ryohei
authors.initials: R
authors.lastname: Nakano
authors.forename: Sharbanee
authors.initials: S
authors.lastname: Mitra
authors.forename: Ryo
authors.initials: R
authors.lastname: Arashida
authors.forename: Yuta
authors.initials: Y
authors.lastname: Asayama
authors.forename: Yukinori
authors.initials: Y
authors.lastname: Yabuta
authors.forename: Takashi
authors.initials: T
authors.lastname: Takeuchi
mesh_terms: D000284:Administration, Oral; D000818:Animals; D003876:Dermatitis, Atopic / Q000473:pathology / Q000517:prevention & control / Q000662:veterinary*; D004423:Ear / Q000033:anatomy & histology / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005056:Euglena gracilis / Q000737:chemistry; D005936:Glucans / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D007114:Immunization / Q000662:veterinary; D051379:Mice; D008815:Mice, Inbred Strains; D010853:Picryl Chloride / Q000494:pharmacology; D012867:Skin / Q000187:drug effects / Q000473:pathology*
chemical_list: D005936:Glucans; C003045:paramylon; D010853:Picryl Chloride